vs
Side-by-side financial comparison of Ensysce Biosciences, Inc. (ENSC) and U S GLOBAL INVESTORS INC (GROW). Click either name above to swap in a different company.
U S GLOBAL INVESTORS INC is the larger business by last-quarter revenue ($2.5M vs $1.9M, roughly 1.3× Ensysce Biosciences, Inc.). U S GLOBAL INVESTORS INC runs the higher net margin — -33.7% vs -147.0%, a 113.3% gap on every dollar of revenue. On growth, Ensysce Biosciences, Inc. posted the faster year-over-year revenue change (44.4% vs 12.5%). Over the past eight quarters, Ensysce Biosciences, Inc.'s revenue compounded faster (107.9% CAGR vs -1.6%).
Ensysce Biosciences, Inc. is a clinical-stage biotechnology firm specializing in developing innovative prodrug therapies for pain management and oncology indications. Its proprietary platform is designed to reduce opioid abuse risks while enhancing treatment efficacy, targeting global healthcare and pharmaceutical markets with a focus on unmet clinical needs.
Allianz Global Investors, is a global investment management firm with offices in over 20 locations worldwide. It is owned by the global financial services group Allianz. Employing nearly 3,000, it manages over EUR 500 billion in assets on behalf of institutional, retail clients and also of Allianz itself. AGI became known for one of the biggest fraud cases in which its Structured Alpha fund lost over 6 billion dollars in the 2020 market sell-off. As the risk profile of the fund was missold to...
ENSC vs GROW — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $1.9M | $2.5M |
| Net Profit | $-2.8M | $-846.0K |
| Gross Margin | — | — |
| Operating Margin | -147.8% | -3.5% |
| Net Margin | -147.0% | -33.7% |
| Revenue YoY | 44.4% | 12.5% |
| Net Profit YoY | 22.3% | -883.7% |
| EPS (diluted) | $-0.51 | $-0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.9M | $2.5M | ||
| Q3 25 | $493.1K | $2.3M | ||
| Q2 25 | $1.4M | $2.0M | ||
| Q1 25 | $1.3M | $2.1M | ||
| Q4 24 | $1.3M | $2.2M | ||
| Q3 24 | $3.4M | $2.2M | ||
| Q2 24 | — | $2.4M | ||
| Q1 24 | — | $2.6M |
| Q4 25 | $-2.8M | $-846.0K | ||
| Q3 25 | $-3.7M | $1.5M | ||
| Q2 25 | $-1.7M | — | ||
| Q1 25 | $-1.9M | $-382.0K | ||
| Q4 24 | $-3.6M | $-86.0K | ||
| Q3 24 | $661.8K | $315.0K | ||
| Q2 24 | — | $315.0K | ||
| Q1 24 | — | $-35.0K |
| Q4 25 | -147.8% | -3.5% | ||
| Q3 25 | -758.7% | -22.9% | ||
| Q2 25 | -127.6% | — | ||
| Q1 25 | -149.1% | -42.5% | ||
| Q4 24 | -274.3% | -24.2% | ||
| Q3 24 | 18.9% | -25.9% | ||
| Q2 24 | — | — | ||
| Q1 24 | — | -18.8% |
| Q4 25 | -147.0% | -33.7% | ||
| Q3 25 | -756.3% | 66.9% | ||
| Q2 25 | -126.4% | — | ||
| Q1 25 | -147.4% | -18.2% | ||
| Q4 24 | -273.4% | -3.9% | ||
| Q3 24 | 19.4% | 14.6% | ||
| Q2 24 | — | 12.9% | ||
| Q1 24 | — | -1.3% |
| Q4 25 | $-0.51 | $-0.07 | ||
| Q3 25 | $-1.29 | $0.12 | ||
| Q2 25 | $-0.79 | — | ||
| Q1 25 | $-1.39 | $-0.03 | ||
| Q4 24 | $-0.89 | $-0.01 | ||
| Q3 24 | $1.00 | $0.02 | ||
| Q2 24 | — | $0.01 | ||
| Q1 24 | — | $0.00 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $4.3M | $34.4M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $3.2M | $44.2M |
| Total Assets | $7.5M | $47.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $4.3M | $34.4M | ||
| Q3 25 | $1.7M | $34.3M | ||
| Q2 25 | $2.2M | $34.2M | ||
| Q1 25 | $3.1M | $36.0M | ||
| Q4 24 | $3.5M | $35.7M | ||
| Q3 24 | $4.2M | $37.0M | ||
| Q2 24 | — | $37.0M | ||
| Q1 24 | — | $37.5M |
| Q4 25 | $3.2M | $44.2M | ||
| Q3 25 | $1.2M | $46.0M | ||
| Q2 25 | $3.4M | $45.2M | ||
| Q1 25 | $3.0M | $46.1M | ||
| Q4 24 | $3.7M | $47.3M | ||
| Q3 24 | $6.9M | $48.4M | ||
| Q2 24 | — | $49.0M | ||
| Q1 24 | — | $49.7M |
| Q4 25 | $7.5M | $47.2M | ||
| Q3 25 | $3.2M | $48.9M | ||
| Q2 25 | $5.6M | $48.1M | ||
| Q1 25 | $4.6M | $48.8M | ||
| Q4 24 | $5.6M | $50.1M | ||
| Q3 24 | $9.4M | $51.1M | ||
| Q2 24 | — | $52.0M | ||
| Q1 24 | — | $52.8M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-1.5M | $256.0K |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-1.5M | $256.0K | ||
| Q3 25 | $-1.9M | $-32.0K | ||
| Q2 25 | $-2.7M | $-822.0K | ||
| Q1 25 | $-1.7M | $-425.0K | ||
| Q4 24 | $-764.1K | $-399.0K | ||
| Q3 24 | $-1.0M | $16.0K | ||
| Q2 24 | — | $990.0K | ||
| Q1 24 | — | $-57.0K |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $-829.0K | ||
| Q1 25 | — | $-426.0K | ||
| Q4 24 | — | $-406.0K | ||
| Q3 24 | — | — | ||
| Q2 24 | — | $777.0K | ||
| Q1 24 | — | $-125.0K |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | -42.3% | ||
| Q1 25 | — | -20.3% | ||
| Q4 24 | — | -18.2% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 31.8% | ||
| Q1 24 | — | -4.8% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 0.4% | ||
| Q1 25 | — | 0.0% | ||
| Q4 24 | — | 0.3% | ||
| Q3 24 | — | 0.0% | ||
| Q2 24 | — | 8.7% | ||
| Q1 24 | — | 2.6% |
| Q4 25 | — | — | ||
| Q3 25 | — | -0.02× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -1.54× | 0.05× | ||
| Q2 24 | — | 3.14× | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
